Trevena Inc (NASDAQ:TRVN)

1.23
Delayed Data
As of Sep 24
 +0.01 / +0.82%
Today’s Change
1.09
Today|||52-Week Range
3.40
-42.52%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$222.1M

Company Description

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Contact Information

Trevena, Inc.
955 Chesterbrook Boulevard
Chesterbrook Pennsylvania 19087
P:(610) 354-8840
Investor Relations:

Employees

Shareholders

Other institutional7.52%
Individual stakeholders13.33%
Mutual fund holders11.82%

Top Executives

Carrie L. BourdowPresident, Chief Executive Officer & Director
Barry ShinChief Financial Officer & Senior Vice President
Mark A. DemitrackChief Medical Officer & Senior Vice President
Angela BagleyVice President-Technical Operations
Michael J. FosslerVP-Clinical Development & Quantitative Sciences